Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Jan 1;101(1):109–119. doi: 10.1172/JCI935

Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes.

A C Crawley 1, G Yogalingam 1, V J Muller 1, J J Hopwood 1
PMCID: PMC508546  PMID: 9421472

Abstract

Mucopolysaccharidosis type VI (MPS VI) is a lysosomal storage disease caused by a deficiency of N-acetylgalactosamine-4-sulfatase (4S). A feline MPS VI model used to demonstrate efficacy of enzyme replacement therapy is due to the homozygous presence of an L476P mutation in 4-sulfatase. An additional mutation, D520N, inherited independently from L476P and recently identified in the same family of cats, has resulted in three clinical phenotypes. L476P homozygotes exhibit dwarfism and facial dysmorphia due to epiphyseal dysplasia, abnormally low leukocyte 4S/betahexosaminidase ratios, dermatan sulfaturia, lysosomal inclusions in most tissues including chondrocytes, corneal clouding, degenerative joint disease, and abnormal leukocyte inclusions. Similarly, D520N/D520N and L476P/D520N cats have abnormally low leukocyte 4S/betahexosaminidase ratios, mild dermatan sulfaturia, lysosomal inclusions in some chondrocytes, and abnormal leukocyte inclusions. However, both have normal growth and appearance. In addition, L476P/D520N cats have a high incidence of degenerative joint disease. We conclude that L476P/D520N cats have a very mild MPS VI phenotype not previously described in MPS VI humans. The study of L476P/D520N and D520N/ D520N genotypes will improve understanding of genotype to phenotype correlations and the pathogenesis of skeletal dysplasia and joint disease in MPS VI, and will assist in development of therapies to prevent lysosomal storage in chondrocytes.

Full Text

The Full Text of this article is available as a PDF (730.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ala-Kokko L., Baldwin C. T., Moskowitz R. W., Prockop D. J. Single base mutation in the type II procollagen gene (COL2A1) as a cause of primary osteoarthritis associated with a mild chondrodysplasia. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6565–6568. doi: 10.1073/pnas.87.17.6565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alroy J., Freden G. O., Goyal V., Raghavan S. S., Schunk K. L. Morphology of leukocytes from cats affected with alpha-mannosidosis and mucopolysaccharidosis VI (MPS VI). Vet Pathol. 1989 Jul;26(4):294–302. doi: 10.1177/030098588902600402. [DOI] [PubMed] [Google Scholar]
  3. Blumenkrantz N., Asboe-Hansen G. New method for quantitative determination of uronic acids. Anal Biochem. 1973 Aug;54(2):484–489. doi: 10.1016/0003-2697(73)90377-1. [DOI] [PubMed] [Google Scholar]
  4. Brooks D. A., McCourt P. A., Gibson G. J., Ashton L. J., Shutter M., Hopwood J. J. Analysis of N-acetylgalactosamine-4-sulfatase protein and kinetics in mucopolysaccharidosis type VI patients. Am J Hum Genet. 1991 Apr;48(4):710–719. [PMC free article] [PubMed] [Google Scholar]
  5. Byers S., Nuttall J. D., Crawley A. C., Hopwood J. J., Smith K., Fazzalari N. L. Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI. Bone. 1997 Nov;21(5):425–431. doi: 10.1016/s8756-3282(97)00175-0. [DOI] [PubMed] [Google Scholar]
  6. Cowell K. R., Jezyk P. F., Haskins M. E., Patterson D. F. Mucopolysaccharidosis in a cat. J Am Vet Med Assoc. 1976 Aug 1;169(3):334–339. [PubMed] [Google Scholar]
  7. Crawley A. C., Brooks D. A., Muller V. J., Petersen B. A., Isaac E. L., Bielicki J., King B. M., Boulter C. D., Moore A. J., Fazzalari N. L. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J Clin Invest. 1996 Apr 15;97(8):1864–1873. doi: 10.1172/JCI118617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Crawley A. C., Niedzielski K. H., Isaac E. L., Davey R. C., Byers S., Hopwood J. J. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Invest. 1997 Feb 15;99(4):651–662. doi: 10.1172/JCI119208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Di Natale P., Annella T., Daniele A., Spagnuolo G., Cerundolo R., de Caprariis D., Gravino A. E. Animal models for lysosomal storage diseases: a new case of feline mucopolysaccharidosis VI. J Inherit Metab Dis. 1992;15(1):17–24. doi: 10.1007/BF01800339. [DOI] [PubMed] [Google Scholar]
  10. Diab M. The role of type IX collagen in osteoarthritis and rheumatoid arthritis. Orthop Rev. 1993 Feb;22(2):165–170. [PubMed] [Google Scholar]
  11. Fillat C., Simonaro C. M., Yeyati P. L., Abkowitz J. L., Haskins M. E., Schuchman E. H. Arylsulfatase B activities and glycosaminoglycan levels in retrovirally transduced mucopolysaccharidosis type VI cells. Prospects for gene therapy. J Clin Invest. 1996 Jul 15;98(2):497–502. doi: 10.1172/JCI118817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Haskins M. E., Aguirre G. D., Jezyk P. F., Patterson D. F. The pathology of the feline model of mucopolysaccharidosis VI. Am J Pathol. 1980 Dec;101(3):657–674. [PMC free article] [PubMed] [Google Scholar]
  13. Haskins M. E., Jezyk P. F., Patterson D. F. Mucopolysaccharide storage disease in three families of cats with arylsulfatase B deficiency: leukocyte studies and carrier identification. Pediatr Res. 1979 Nov;13(11):1203–1210. doi: 10.1203/00006450-197911000-00001. [DOI] [PubMed] [Google Scholar]
  14. Helminen H. J., Kiraly K., Pelttari A., Tammi M. I., Vandenberg P., Pereira R., Dhulipala R., Khillan J. S., Ala-Kokko L., Hume E. L. An inbred line of transgenic mice expressing an internally deleted gene for type II procollagen (COL2A1). Young mice have a variable phenotype of a chondrodysplasia and older mice have osteoarthritic changes in joints. J Clin Invest. 1993 Aug;92(2):582–595. doi: 10.1172/JCI116625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hopwood J. J., Elliott H., Muller V. J., Saccone G. T. Diagnosis of Maroteaux-Lamy syndrome by the use of radiolabelled oligosaccharides as substrates for the determination of arylsulphatase B activity. Biochem J. 1986 Mar 15;234(3):507–514. doi: 10.1042/bj2340507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hopwood J. J., Harrison J. R. High-resolution electrophoresis of urinary glycosaminoglycans: an improved screening test for the mucopolysaccharidoses. Anal Biochem. 1982 Jan 1;119(1):120–127. doi: 10.1016/0003-2697(82)90674-1. [DOI] [PubMed] [Google Scholar]
  17. Hopwood J. J., Vellodi A., Scott H. S., Morris C. P., Litjens T., Clements P. R., Brooks D. A., Cooper A., Wraith J. E. Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype. J Inherit Metab Dis. 1993;16(6):1024–1033. doi: 10.1007/BF00711520. [DOI] [PubMed] [Google Scholar]
  18. Kampine J. P., Brady R. O., Kanfer J. N., Feld M., Shapiro D. Diagnosis of gaucher's disease and niemann-pick disease with small samples of venous blood. Science. 1967 Jan 6;155(3758):86–88. doi: 10.1126/science.155.3758.86. [DOI] [PubMed] [Google Scholar]
  19. Keller C., Briner J., Schneider J., Spycher M., Rampini S., Gitzelmann R. Mukopolysaccharidose Typ VI-A (Morbus Maroteaux-Lamy): Korrelation der klinischen und pathologisch-anatomischen Befunde bei einem 27jährigen Patienten. Helv Paediatr Acta. 1987;42(4):317–333. [PubMed] [Google Scholar]
  20. Lewis D. M., Lewis J. C., Loegering D. A., Gleich G. J. Localization of the guinea pig eosinophil major basic protein to the core of the granule. J Cell Biol. 1978 Jun;77(3):702–713. doi: 10.1083/jcb.77.3.702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Litjens T., Brooks D. A., Peters C., Gibson G. J., Hopwood J. J. Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Am J Hum Genet. 1996 Jun;58(6):1127–1134. [PMC free article] [PubMed] [Google Scholar]
  22. Metcalfe D. D., Bland C. E., Wasserman S. I. Biochemical and functional characterization of proteoglycans isolated from basophils of patients with chronic myelogenous leukemia. J Immunol. 1984 Apr;132(4):1943–1950. [PubMed] [Google Scholar]
  23. Nakata K., Ono K., Miyazaki J., Olsen B. R., Muragaki Y., Adachi E., Yamamura K., Kimura T. Osteoarthritis associated with mild chondrodysplasia in transgenic mice expressing alpha 1(IX) collagen chains with a central deletion. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2870–2874. doi: 10.1073/pnas.90.7.2870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Orenstein N. S., Galli S. J., Dvorak A. M., Silbert J. E., Dvorak H. F. Sulfated glycosaminoglycans of guinea pig basophilic leukocytes. J Immunol. 1978 Aug;121(2):586–592. [PubMed] [Google Scholar]
  25. Parmley R. T., Takagi M., Spicer S. S., Thrasher A., Denys F. R. Ultrastructural visualization of complex carbohydrates in eosinophilic leukocytes. Am J Anat. 1982 Sep;165(1):53–67. doi: 10.1002/aja.1001650106. [DOI] [PubMed] [Google Scholar]
  26. Paterson D. E., Harper G., Weston H. J., Mattingley J. Maroteaux-Lamy syndrome, mild form--MPS vi b. Br J Radiol. 1982 Nov;55(659):805–812. doi: 10.1259/0007-1285-55-659-805. [DOI] [PubMed] [Google Scholar]
  27. Peters M. S., Rodriguez M., Gleich G. J. Localization of human eosinophil granule major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin by immunoelectron microscopy. Lab Invest. 1986 Jun;54(6):656–662. [PubMed] [Google Scholar]
  28. Pilz H., von Figura K., Goebel H. H. Deficiency of arylsulfatase B in 2 brothers aged 40 and 38 years (Maroteaux-Lamy syndrome, type B). Ann Neurol. 1979 Oct;6(4):315–325. doi: 10.1002/ana.410060405. [DOI] [PubMed] [Google Scholar]
  29. Quigley H. A., Kenyon K. R. Ultrastructural and histochemical studies of a newly recognized form of systemic mucopolysaccharidosis. (Maroteaux-Lamy syndrome, mild phenotype). Am J Ophthalmol. 1974 Jun;77(6):809–818. doi: 10.1016/0002-9394(74)90383-3. [DOI] [PubMed] [Google Scholar]
  30. Schönherr E., Hausser H., Beavan L., Kresse H. Decorin-type I collagen interaction. Presence of separate core protein-binding domains. J Biol Chem. 1995 Apr 14;270(15):8877–8883. doi: 10.1074/jbc.270.15.8877. [DOI] [PubMed] [Google Scholar]
  31. Spranger J. W., Koch F., McKusick V. A., Natzschka J., Wiedemann H. R., Zellweger H. Mucopolysaccharidosis VI (Maroteaux-Lamy's disease). Helv Paediatr Acta. 1970 Oct;25(4):337–362. [PubMed] [Google Scholar]
  32. Tønnesen T., Gregersen H. N., Güttler F. Normal MPS excretion, but dermatan sulphaturia, combined with a mild Maroteaux-Lamy phenotype. J Med Genet. 1991 Jul;28(7):499–501. doi: 10.1136/jmg.28.7.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Vogel K. G., Paulsson M., Heinegård D. Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem J. 1984 Nov 1;223(3):587–597. doi: 10.1042/bj2230587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ward J. M., Wright J. F., Wharran G. H. Ultrastructure of granulocytes in the peripheral blood of the cat. J Ultrastruct Res. 1972 May;39(3):389–396. doi: 10.1016/s0022-5320(72)90030-5. [DOI] [PubMed] [Google Scholar]
  35. Wicker G., Prill V., Brooks D., Gibson G., Hopwood J., von Figura K., Peters C. Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An intermediate clinical phenotype caused by substitution of valine for glycine at position 137 of arylsulfatase B. J Biol Chem. 1991 Nov 15;266(32):21386–21391. [PubMed] [Google Scholar]
  36. Yogalingam G., Litjens T., Bielicki J., Crawley A. C., Muller V., Anson D. S., Hopwood J. J. Feline mucopolysaccharidosis type VI. Characterization of recombinant N-acetylgalactosamine 4-sulfatase and identification of a mutation causing the disease. J Biol Chem. 1996 Nov 1;271(44):27259–27265. doi: 10.1074/jbc.271.44.27259. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES